V irus-specific CD4
ϩ T lymphocytes play a central role in the immune containment of HIV. They contribute to HIV clearance both by providing help for B cell responses and by maintaining effective CTL (1, 2) . Recent studies suggest that functional CD4 ϩ T lymphocytes are also required at the time of immune priming for the development of memory CD8 ϩ T lymphocytes (3) (4) (5) . CD4 ϩ T lymphocytes of HIV-infected individuals display functional defects, including reduced proliferative responses to both Ags and mitogens (6) . These functional CD4 ϩ T lymphocyte defects are associated with reduced production of IL-2, which can be partially corrected in vitro by the addition of exogenous IL-2 (7, 8) . The integrity of CD4 ϩ T lymphocytes that secrete IL-2, or a subset of CD4 ϩ T lymphocytes that secrete both IFN-␥ and IL-2, is associated with good clinical outcome in HIV-infected individuals (9 -11) . Thus, production of IL-2 by CD4 ϩ T lymphocytes is important for the maintenance of a functional immune system in infected individuals. CD4 ϩ T lymphocytes have been divided into central memory and effector memory cell subsets based on their homing capacity and effector function (12, 13) . Central memory T lymphocytes home to lymphoid organs, have little or no effector function, produce predominantly IL-2, and have a high capacity to proliferate. In contrast, effector memory T lymphocytes migrate to peripheral tissues, display effector function, produce primarily IFN-␥, and lack significant proliferative capacity. Precisely how the defective cellular production of cytokines is associated with the development of memory CD4 ϩ T lymphocytes in HIV-infected individuals remains to be elucidated.
In the present study, the cytokine production of CD4 ϩ T lymphocyte subsets was analyzed in rhesus monkeys infected with pathogenic viruses and attenuated viruses, and in vaccinated monkeys that were protected from developing disease following pathogenic simian human immunodeficiency virus (SHIV) 3 challenge. The results of this study suggest that the ability of SIV/SHIVstimulated central memory CD4
ϩ T lymphocytes to synthesize IL-2 is an immune correlate of disease protection following primate immunodeficiency virus infection.
Materials and Methods

Animals and viruses
Heparinized blood samples were obtained from rhesus monkeys (Macaca mulatta). All animals were maintained in accordance with the guidelines of the Committee on Animals for the Harvard Medical School and the Guide for the Care and Use of Laboratory Animals (14) . Viruses used in this study were the nonpathogenic SHIV-89.6, the pathogenic SHIV-89.6P, the pathogenic SIVmac251, the attenuated J5 strain of SIVmac251, and the pathogenic SIVsmE660.
CD4
ϩ T lymphocyte counts and plasma viral RNA levels
Peripheral blood CD4 ϩ T lymphocyte counts were calculated by multiplying the total lymphocyte count by the percentage of CD3 ϩ CD4 ϩ T cells determined by mAb staining and flow cytometric analysis. Plasma viral RNA levels were measured by an ultrasensitive branched DNA amplification assay with a detection limit of 125 copies per ml (Bayer Diagnostics).
Vaccination protocol
Three groups of vaccinated monkeys were included in this study (Table I ). The first group of monkeys (vaccinated/SHIV-89.6P challenged) was immunized three times by the i.m. route with 10 mg of plasmid DNA containing SIVmac239 Gag/Pol/Nef, with or without HIV-1 89.6P Env. Following an 18-wk rest, each of the DNA-primed monkeys was boosted with 2 ϫ 10 12 PFU of recombinant adenovirus serotype 5 (rAd5) expressing the same SIV/HIV-1 genes by the i.m. route. Animals were challenged at wk 38 with 100 50% monkey infectious doses (MID 50 ) of SHIV-89.6P by the i.v. route. The second group of monkeys (vaccinated only) was immunized two to four times by the i.m. route with plasmid DNA containing gag, pol, nef, and env genes encoding for CTL epitopes (15) , and boosted by i.m. injection with recombinant modified vaccinia virus Ankara (MVA), vaccinia virus, or rAd5 constructs. The third group of monkeys (vaccinated only) either was immunized three times by i.m. route with 10 mg of plasmid DNA containing SIVmac239 Gag/Pol/Nef and HIV-1 89.6P Env, or received no plasmid DNA immunization. Following an 18-wk rest, all DNA-primed monkeys, as well as a group of naive monkeys, received 2 ϫ 10 12 PFU of rAd5 expressing the same SIV/HIV-1 genes. Monkeys received a second inoculation of rAd5 constructs 133 wk later.
Antibodies
The Abs used in this study were directly coupled to FITC, PE, PE-Texas Red (ECD), allophycocyanin, PerCP-Cy5.5, Alexa Fluor 700, or PE-Cy7. 
PBMC stimulation and intracellular cytokine staining
PBMC were separated from whole blood by Ficoll density gradient centrifugation. PBMC (10 6 ) were incubated at 37°C in a 5% CO 2 environment for 6 h in the presence of RPMI 1640/10% FCS medium alone (unstimulated), a pool of 15-mer Gag peptides (5 g/ml each peptide), or staphylococcal enterotoxin B (SEB) (5 g/ml, Sigma-Aldrich) as a positive control. All cultures contained Monensin (GolgiStop; BD Biosciences) as well as 1 g/ml anti-CD49d (BD Biosciences). The cultured cells were stained with mAbs specific for cell surface molecules before fixation. The PBMC were washed twice with PBS-2% FCS and then fixed and permeabilized with Cytofix/Cytoperm solution (BD Biosciences) in accordance with the manufacturer's protocol. Cells were washed twice with 1ϫ Perm/Wash buffer (BD Biosciences) and then stained with anti-cytokine mAb. Anticytokine mAb titers for optimal staining were determined in preliminary experiments. Cells were washed twice with 1ϫ Perm/Wash buffer and then fixed in 1.5% formaldehyde-PBS. The following mAb combinations were used: CD28-FITC/CD95-PE/CD4-ECD/cytokine-allophycocyanin (IFN-␥, IL-2, and TNF-␣) and CD28-FITC/CD95-PE/CD8␣-ECD/IL-2-allophycocyanin/CD4-PerCP-Cy5.5/CD3-Alexa700/IFN-␥-PE-Cy7. Samples were collected either on a FACSCalibur instrument (BD Biosciences) and analyzed with CellQuest software (BD Biosciences) or on a LSR II instrument (BD Biosciences) and analyzed using FlowJo software (Tree Star). Approximately 100,000 to 300,000 events in the lymphocyte gate were acquired. The background level of cytokine staining varied from sample to sample, but was typically Ͻ0.04% of the CD4 ϩ T lymphocytes. The only samples considered positive were those in which the percentage of cytokine-staining cells was at least twice that of the background or in which there was a distinct population of cytokine brightly positive cells. 
Statistical analyses
Results
IL-2, IFN-␥, and TNF-␣ production by CD4 ϩ T lymphocytes in naive, vaccinated, and SIV/SHIV-infected rhesus monkeys
To determine the functional capacity of CD4 ϩ T lymphocytes from naive, vaccinated, and SIV/SHIV-infected rhesus monkeys, the expression of selected cytokines by SEB-stimulated lymphocytes was first characterized. One of the cohorts of vaccinated animals that was evaluated received plasmid DNA prime and recombinant poxvirus boost immunizations 6 mo before evaluation FIGURE 1. Cytokine expression profiles of CD4 ϩ T lymphocytes of normal, vaccinated, and SIV/SHIV-infected rhesus monkeys. The evaluated animals included healthy, uninfected monkeys; monkeys primed with plasmid DNA and boosted with a recombinant poxvirus vaccine or recombinant adenovirus vaccine; monkeys infected with attenuated SIV/SHIV; and monkeys infected with pathogenic SIV isolates. CD4
ϩ T lymphocyte responses to SEB (A) or pooled Gag peptides (B) were measured. IFN-␥, IL-2, and TNF-␣ expression are shown as percent positive CD4 ϩ T lymphocytes. Values for each monkey are depicted as separate points, and the bars represent the median value for each group. Nonresponders (zero values) are shown on the base of each log plot at the frequency of 0.01. The Kruskal-Wallis test was used to evaluate significant differences between groups (bolded p values), and the Mann-Whitney U test was used to investigate the statistical significance of the individual data pairs. To account for multiple comparisons, the p values were adjusted by the Holm's method. Statistically significant differences using this test are highlighted in the figure by an asterisk ‫.)ء(‬ ( Table I ). The other cohort of vaccinated monkeys that was studied was given plasmid DNA prime and recombinant adenovirus boost immunizations 5 wk before analysis (Table I) . Because the monkeys vaccinated by either of the regimens developed comparable immune responses, the data from both cohorts were combined for purpose of analysis. Monkeys infected with nonpathogenic SHIV-89.6, attenuated SIVmac251(J5), or highly pathogenic SIVmac251 and SIVsmE660 isolates were characterized to determine plasma viral RNA levels and CD4 ϩ T lymphocyte counts (Table II) . No statistically significant differences were noted in the frequencies of IFN-␥-, IL-2-, and TNF-␣-producing CD4 ϩ T lymphocytes in response to SEB from normal, vaccinated, and infected monkeys (Kruskal-Wallis test) (Fig. 1A) . However, a trend toward lower frequencies of IFN-␥-and IL-2-producing CD4 ϩ lymphocytes was seen in monkeys infected with the pathogenic SIV isolates. We also noticed markedly decreased in vitro viability of PBMC from monkeys with advanced disease following stimulation with SEB, with the remaining CD4 ϩ T cells having no cytokine-producing capacity after stimulation (data not shown). Of note, monkeys infected with pathogenic SIV isolates had significantly lower frequencies of Gag-specific IL-2-producing CD4 ϩ T cells than those infected with nonpathogenic virus ( p ϭ 0.027, Holm's test) (Fig. 1B) . Thus, the capacity of Gag-specific CD4 ϩ T lymphocytes to express IL-2 was associated with the clinical status of the infected monkeys.
Gag-specific IFN-␥
ϩ alone, IL-2 ϩ alone, and
cell frequencies in monkeys infected with attenuated SIV/SHIV or pathogenic SIV isolates
Recent studies have shown that the maintenance of a subset of HIV-specific CD4 ϩ T cells that produce both IFN-␥ and IL-2 is associated with good clinical outcome in HIV-infected individuals (11) . We therefore sought to determine whether the loss of IL-2-producing cells in the monkeys infected with pathogenic virus reflected a loss of cells producing IL-2 alone or cells producing IL-2 and IFN-␥. To this end, we quantitated Gag-specific CD4 ϩ T cells that were IFN-␥ ϩ alone, IL-2 ϩ alone, and IFN-␥ ϩ IL-2 ϩ in PBMC of monkeys infected with attenuated SIV/SHIV and of monkeys infected with pathogenic SIV isolates (Fig. 2 ). PBMC were stained simultaneously for both IFN-␥ and IL-2, and the frequency of CD4 ϩ T cells that produced IFN-␥ or IL-2, as well as cells that produced both IFN-␥ and IL-2 was measured in a seven-color flow cytometric assay. The percentage of Gag-specific CD4 ϩ T cells producing IFN-␥ alone was similar in PBMC of both groups of monkeys. However, the median frequency of Gag-specific IFN-
ϩ CD4 ϩ T cell responses was significantly higher in monkeys infected with the attenuated SIV/SHIV than in monkeys infected with pathogenic SIV isolates ( p ϭ 0.034). Moreover, although very few Gag-specific CD4 ϩ T cells produced IL-2 alone in the evaluated monkeys, a trend toward lower frequencies of these cells was seen in monkeys infected with pathogenic SIV ϩ T cell subsets was evaluated. Lymphocytes from five healthy, uninfected monkeys were studied. The symbols ϩϩ, ϩ, and Ϫ reflect the relative staining intensities of the anti-CD28 mAb.
FIGURE 4.
Maturation and function-associated molecules on naive and memory subsets of CD4 ϩ T lymphocytes from normal, vaccinated, and SIV/SHIV-infected rhesus monkeys. A, The expression of CD28 and CD95 on peripheral blood CD4 ϩ T lymphocytes of healthy uninfected monkeys (n ϭ 5), monkeys primed with plasmid DNA and boosted with a recombinant poxvirus vaccine (n ϭ 6), monkeys infected with attenuated SIV/ SHIV (n ϭ 5), and monkeys infected with pathogenic SIV isolates (n ϭ 10). B, Comparison of the expression of molecules associated with maturation and function on CD4
ϩ T lymphocyte subsets defined by CD28 and CD95 expression in each of these four groups of monkeys. The interquartile range is indicated for each bar.
isolates than in monkeys infected with attenuated virus ( p ϭ 0.054). These results suggest that the presence of Ag-specific CD4 ϩ T cells able to produce IL-2 is associated with effective immune control of virus.
Cell surface characterization of CD4 ϩ T lymphocytes: maturation and functional markers on lymphocyte subsets defined on the basis of CD28 and CD95 expression
The expression of CD28 and CD95 has been used to define distinct subsets of CD4 ϩ T lymphocytes (16) . Naive CD4 ϩ T cells can be identified by their intermediate expression of CD28 and lack of CD95 expression. Memory CD4 ϩ T cells acquire CD95 expression and can be divided into central memory and effector memory subsets based on CD28 expression.
To examine the expression of other putative naive and memory cell-associated surface molecules on rhesus monkey CD4 ϩ T lymphocytes, we performed phenotypic and functional analyses of PBMC defined by CD28 and CD95 expression in five normal animals. Naive CD4 ϩ T cells (CD28 ϩ CD95 Ϫ ) were homogenous small lymphocytes that expressed moderate-to-high levels of lymphoid tissue-homing molecules (CCR7 ϩ , CD62L ϩ ), low levels of adhesion molecules (CD11a low ), and lacked expression of CCR5, a molecule associated with homing to effector sites (Fig. 3) . These cells showed minimal proliferation (Ki67 Ϫ , Bcl-2 high ) and no effector function (no cytokine production capacity, Granzyme B Ϫ ). In contrast, effector memory CD4 ϩ T cells (CD28 Ϫ CD95 ϩ ) expressed cell surface molecules that facilitate homing to effector sites (CCR7 Ϫ , CD62L Ϫ , CD11a high , CCR5 ϩ/Ϫ ). They had phenotypic characteristics of effector cells (Granzyme B ϩ , and were capable of producing IFN-␥ and TNF-␣). Central memory CD4 ϩ T cells (CD28 ϩ CD95 ϩ ) had a different phenotypic profile. Twothirds of the central memory CD4
ϩ T cells were CCR7 ϩ . The central memory CD4 ϩ T cells had the capacity to produce IL-2 and proliferate, but lacked cytotoxic effector function (Granzyme B Ϫ ). Some naive and central memory CD4 ϩ T cells were CD25 ϩ and may therefore have regulatory function. These observations confirmed that the rhesus monkey CD4 ϩ T lymphocyte subsets defined by CD28 and CD95 expression exhibited physiologic characteristics of naive, central memory, and effector memory CD4 ϩ T cells as previously described (12, 16) .
Maturation and function of CD4 ϩ T lymphocytes in naive, vaccinated, and SIV/SHIV-infected rhesus monkeys
Having demonstrated a loss of IL-2 production by Gag-specific CD4 ϩ T cells in monkeys with progressive disease (Fig. 1B) , we sought to determine whether this reflected changes in the relative representation of naive and memory CD4 ϩ T cells in the peripheral blood of these animals or resulted from the loss of cytokine production capacity by a particular subset of CD4 ϩ T cells. We therefore evaluated naive and memory CD4 ϩ T cells defined by CD28 and CD95 expression in the naive, vaccinated, and infected cohorts 
CD4
ϩ T cells compared with the other groups ( p ϭ 0.005) (Fig. 4B) . Taken together, these data suggest that the loss of IL-2 production by Gag-specific CD4 ϩ T cells in monkeys with progressive disease is not associated with depletion of naive or memory T cell subsets. However, as expected, there was a decrease in cells that might serve as targets for SIV infection (CD4
Cytokine expression by CD4 ϩ T cell subsets in naive, vaccinated, and pathogenic SIV-infected monkeys
To evaluate further the functional activity of CD4 ϩ T cell subsets in normal, vaccinated, and SIV-infected monkeys, cytokine production by central memory and effector memory cells was analyzed (Fig. 5) . In normal monkeys, SEB-induced IFN-␥ production by CD4 ϩ T lymphocytes was found predominantly in the effector memory cell population (median, 19.2 vs 4.97%). Conversely, IL-2 production by SEB-stimulated CD4 ϩ T lymphocytes originated predominantly from central memory cells (median, 8.98 vs 2.77%). TNF-␣ expression was comparable in SEB-stimulated central memory and effector memory CD4 ϩ T lymphocytes (median, 15.34 vs 20.47%). No significant differences in SEB-induced cytokine expression patterns were observed between the CD4 ϩ T lymphocyte populations of vaccinated and normal monkeys. However, there was a significant decrease of IL-2 expression by central memory CD4
ϩ T cells of monkeys infected with pathogenic virus (Fig. 5A) . A trend toward a statistical difference between the normal monkeys and the monkeys infected with pathogenic virus in the SEB-stimulated IL-2-producing CD4 ϩ T cells was also seen.
In contrast, Ag stimulation by a Gag peptide pool induced very different cytokine expression patterns in subpopulations of CD4 ϩ T lymphocytes of vaccinated or SIV-infected monkeys (Fig. 5B ). There were low but measurable levels of IFN-␥, IL-2, or TNF-␣ expression by Gag-specific CD28 Ϫ CD95 ϩ effector memory cells. Cytokine production by Gag-specific CD4 ϩ T lymphocytes was found predominantly in cells with a central memory phenotype (CD28 ϩ CD95 ϩ ). A selective decrease in IL-2 expression was seen in central memory CD4
ϩ T cells of monkeys with progressive clinical disease, sometimes in the absence of changes in the expression of IFN-␥ or TNF-␣. These data suggest that loss of IL-2 production by Gag-specific CD4 ϩ T cells in monkeys with progressive disease does not reflect changes in the relative representation of naive and memory CD4 ϩ T cells in the peripheral blood of these animals. Rather, it results from the loss of IL-2 production capacity by central memory CD4 ϩ T cells.
Naive and memory CD4 ϩ T lymphocytes are present in blood and peripheral lymph nodes of infected rhesus monkeys
Because it has been shown that central memory CD4
ϩ T cells can preferentially be found in lymphoid tissues, we sought to determine whether the frequency of central memory CD4
ϩ T cells was high enough in the peripheral blood to reflect the biology of this cell subpopulation. We therefore compared the relative frequencies of naive and memory phenotype CD4 ϩ T cells in the peripheral blood and the secondary lymphoid tissues in infected monkeys. Data from a representative monkey with a normal CD4 ϩ T cell count and undetectable viral load are shown in Fig. 6 . Central memory CD4
ϩ T cell frequencies in peripheral blood tended to be a little lower than frequencies in the lymph node, and as expected, effector memory CD4 ϩ T cells were absent from the lymph node. More importantly, Gag-specific cytokine-producing CD4 ϩ T cells were present at twice the frequency in the peripheral blood than in the lymph node. Thus, central memory CD4
ϩ T lymphocytes in the peripheral blood should reflect those seen in lymph nodes.
Vaccine protection against SHIV-induced clinical disease is associated with preserved central memory CD4 ϩ T lymphocyte function
We next assessed cytokine expression profiles of Gag-specific CD4 ϩ T cells from a cohort of monkeys that was vaccinated and subsequently challenged with SHIV-89.6P (Tables I and III) . In this cohort, monkeys were vaccinated first with plasmid DNA and then with recombinant adenovirus constructs expressing SIV Gag/ Pol/Nef with or without HIV-1 Env. Following challenge with SHIV-89.6P, all vaccinated monkeys maintained low plasma viral RNA levels and normal peripheral blood CD4 ϩ T lymphocyte counts. Three monkeys that received Gag/Pol/Nef but no Envcontaining vaccines had relatively high plasma viral RNA levels and reduced CD4 ϩ T lymphocyte counts. Gag peptide-stimulated CD4 ϩ T lymphocyte cytokine expression profiles were assessed in PBMC of these monkeys 15 mo postchallenge.
Similar to monkeys infected with attenuated SIV/SHIV, IL-2 production by central memory CD4
ϩ T cells of the vaccinated/ challenged monkeys was better preserved than IL-2 production by central memory CD4
ϩ T cells in monkeys infected with pathogenic virus in the absence of prior vaccination ( p ϭ 0.014, Holm's test) (Fig. 7A ). The only vaccinated and then challenged monkeys that did not demonstrate preserved SIV Gag-stimulated IL-2 production by central memory CD4
ϩ T lymphocytes were those with high plasma viral RNA levels. These results demonstrate that vaccine protection against SHIV-induced clinical disease is associated with preserved central memory CD4
ϩ T lymphocyte function.
Correlation between the frequency of IL-2-producing central memory CD4 ϩ T cells and plasma viral RNA levels
The observed association between high viral loads and loss of Gag-specific IL-2-producing central memory CD4 ϩ T cells in this group of vaccinated/challenged monkeys suggested that such an association be evaluated in a larger cohort of animals. Therefore, the frequencies of Gag-specific IL-2-producing central memory CD4 ϩ T cells were assessed for an association with plasma viral RNA levels for all evaluated monkeys, including monkeys infected with attenuated SIV/SHIV, monkeys infected with pathogenic virus, and monkeys vaccinated and challenged with SHIV-89.6P. A significant inverse correlation was observed between these parameters (r ϭ Ϫ0.70, p Ͻ 0.0001) (Fig. 8) . However, no significant correlation was noted between IFN-␥ or TNF-␣ production by central memory CD4
ϩ T cells and the plasma viral RNA levels in these animals (data not shown). Therefore, the maintenance of IL-2-producing central memory CD4
ϩ T cells is ultimately associated with virologic control in the monkeys.
Discussion
Although IFN-␥ production assays are commonly used to measure T lymphocyte immune responses to HIV Ags, these analyses do not reflect the complete profile of the functional capacity of HIVspecific T cells. In fact, considerable recent work suggests that the production of other cytokines by CD4 ϩ T lymphocytes plays an important functional role in disease pathogenesis. IL-2 is essential to the expansion and survival of T lymphocytes, and accruing data suggest that IL-2-secreting Ag-specific CD4 ϩ T lymphocytes represent a key component of an effective immune response (7, 11, 17) . In the present study, CD4
ϩ T lymphocytes of infected monkeys with uncontrolled viremia and reduced CD4 ϩ T lymphocyte counts preserved their capacity to produce IFN-␥ and TNF-␣, whereas their ability to synthesize IL-2 was impaired. Therefore, the preservation of Gag-specific IL-2-producing CD4 ϩ T lymphocytes is associated with effective immune control of virus. IL-2 production by CD4 ϩ T lymphocytes may be lost during an early stage of disease in these monkeys, with a loss of IFN-␥ and TNF-␣ production as disease progresses. This possibility is consistent with the recent finding that lymphocytic choriomeningitis virus-specific T cells lose their ability to produce IL-2 before their ability to produce TNF-␣ and IFN-␥ as lymphocytic choriomeningitis virusinduced disease progresses in mice (18) .
A number of studies have shown that Ag-specific CD8 ϩ T cells can be separated into three functional subsets: early-, intermediate-, and late-differentiated phenotypes. HIV-specific CD8 ϩ T lymphocytes can exist in an intermediate differentiated state in the peripheral blood of infected individuals (19, 20) . A similar maturation phenotype has also been observed for HIV-specific CD4 ϩ T lymphocytes in the peripheral blood of these individuals (21, 22) . The phenotypic profiles of the SIV Gag-specific CD4 ϩ T cells of the infected monkeys evaluated in the present study are consistent with this intermediate differentiated state. Cytokine production by Gag-specific CD4 ϩ T lymphocytes was found predominantly in cells with a central memory phenotype (CD28 ϩ CD95 ϩ ). The reason for this atypical state of T cell maturation is likely multifactorial. First, because compartmentalization of T lymphocyte subpopulations may occur, the population of cells identified in the peripheral blood of infected individuals might reflect changes in T cell trafficking and are not necessarily representative of the entire virus-specific T cell population. Second, intermediate T cell differentiation may reflect the normal immune response to an immunodeficiency virus during chronic infection. HIV-specific CD4 ϩ T cells that have a central memory/effector memory phenotype may be targeted to lymph nodes where HIV replication is ongoing. A third possible explanation for this atypical T cell maturation is that replicating HIV may inhibit or redirect T cell differentiation and, in so doing, affect the clinical course of disease progression. Conflicting data have been reported bearing on this last possibility. Some investigators have reported that, although HIV-specific CD4 ϩ T cells are less mature than CMV-specific CD4 ϩ T cells, there is no correlation between HIV-specific T cell maturation and disease progression (22) . Other investigators have reported that HIV-1 replication skews Gag-specific CD4 ϩ T cells away from an IL-2-producing central memory phenotype and toward a poorly proliferating effector memory phenotype, and this change may limit the effectiveness of the HIV-specific immune response (23) .
These conflicting results may reflect the different approaches used by these investigators to define naive, central memory, and effector memory T lymphocyte subsets. CD4 ϩ T lymphocytes have been divided into three major functional subsets on the basis of their expression of pairs of surface molecules (12, 20, 24) . The pairing molecules used for such studies include CCR7 or CD62L with CD45RA, CD28 with CD27, and CD28 or CD27 with CD45RA. However, it is very likely that a more precise definition of functional subsets of cells can be accomplished using mAbs that bind to additional surface molecules. For example, CD28
ϩ CD45RA Ϫ central memory T cells might be further divided into CD28 ϩ CD45RA Ϫ CCR7 ϩ and CD28 ϩ CD45RA
Ϫ CCR7 Ϫ T cell subpopulations. Therefore, a more precise definition of functional T lymphocyte subpopulations may facilitate an elucidation of the role of these cells in disease pathogenesis.
In the present study, surface expression of CD28 and CD95 has been used to define CD4 ϩ T lymphocyte subsets. We showed that cell subpopulations defined in this way have physiologic characteristics of naive, central memory, and effector memory CD4 ϩ T cells as has been previously described (16, 25) . Most of the cytokine production by Gag-specific CD4 ϩ T lymphocytes was contributed by cells with a CD28 ϩ CD95 ϩ central memory phenotype. This was true in healthy vaccinated monkeys, and in monkeys infected with pathogenic virus. The consistency of these findings suggests that the function of SIV-specific CD4 ϩ T cells with a central memory phenotype is correlated with disease progression. Finally, it is also possible that late effector cells that acquire CCR5 expression become targets for HIV infection, and are therefore depleted. This would result in cells of intermediate-differentiated phenotype being detected predominantly in infected individuals with progressive disease.
We and others have previously shown that monkeys vaccinated and challenged with a pathogenic immunodeficiency virus have low viral loads, preserved CD4 ϩ counts, and no evidence of clinical disease (26 -28) . However, the mechanism accounting for this persistent clinical protection is poorly understood. In the present study, we show that the central memory CD4 ϩ T lymphocytes from such vaccinated and then infected monkeys had a preserved capacity to produce IL-2, comparable with that seen in animals that were infected with nonpathogenic virus. This observation suggests that persistent clinical protection in vaccinated and challenged monkeys is correlated with a preserved capacity of the peripheral blood central memory CD4
ϩ T cells to express virus-induced immunomodulatory cytokine IL-2.
